• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Hikma Pharmaceuticals Plc.
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.7679 +0.0351 (+4.79%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,193,985
Open 0.7100
Bid (Size) 0.7630 (1,000)
Ask (Size) 0.7747 (4,400)
Prev. Close 0.7328
Today's Range 0.7100 - 0.8198
52wk Range 0.6909 - 2.725
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy ↗
November 12, 2026
Ocugen (NASDAQ:OCGN) expects pivotal data for its lead experimental gene therapy for retinitis pigmentosa in the first quarter of 2027, a milestone that could set up a regulatory filing later that... 
Via MarketBeat
News headline image
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
November 10, 2026
From Ocugen
Via GlobeNewswire

Performance

52-Week Range 71.8% below 52-week high
0.7679
0.6952W Low 2.7352W High
1 Week 6.4% below 1-week high
0.711W Low 0.821W High

Ocugen, Inc. - Common Stock (OCGN) traded between $0.69 and $2.73 over the past 52 weeks and last traded at $0.77, 71.8% below its 52-week high. Over the past week it ranged between $0.71 and $0.82.

Past 12 Months
-0.7%
-5.8%
-44.8%
-42.7%
-44.4%
-30.8%
1W -$0.01
1M -$0.05
3M -$0.62
6M -$0.57
YTD -$0.61
1Y -$0.34

OCGN was -30.8% over the past year, -42.7% over six months, -44.4% year to date, -0.7% in the last week.

12 Months vs Market
OCGN
-30.8%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months OCGN returned -30.8% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 0.85× 3-mo avg
Today 6,193,985 3-mo avg 7.3M
1W
7.2M
1M
7.4M
3M
7.3M
6M
6.9M
YTD
7.2M
1Y
6.8M

OCGN most recently traded 6,193,985 shares against a 3-month average daily volume of 7.3M.

More News

Read More
News headline image
Ocugen Q3 Earnings Call Highlights ↗
November 04, 2026
Via MarketBeat
Topics Earnings
News headline image
Ocugen (OCGN) Q3 2026 Earnings Call Transcript ↗
November 04, 2026
Via The Motley Fool
Topics Earnings
Ocugen (NASDAQ:OCGN) Falls on Mixed Q2 Results as Revenue Beat Offsets Wider Loss ↗
August 06, 2026
Via Chartmill
News headline image
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
November 04, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming November Investor and Industry Conferences
October 29, 2026
From Ocugen
Via GlobeNewswire
News headline image
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
October 28, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
October 22, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
October 14, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
October 06, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming Scientific Conferences
September 30, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming October Investor and Industry Conferences
September 29, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
September 25, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances ↗
September 16, 2026
Via MarketBeat
News headline image
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
September 01, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming September Investor and Industry Conferences
August 25, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts ↗
August 15, 2026
Via MarketBeat
News headline image
Ocugen (OCGN) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings Retirement
News headline image
Ocugen Q2 Earnings Call Highlights ↗
August 07, 2026
Via MarketBeat
Topics Earnings
News headline image
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
August 06, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming August Investor Conferences
July 31, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
July 29, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
July 28, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
July 13, 2026
From Ocugen
Via GlobeNewswire

Frequently Asked Questions

Is Ocugen, Inc. - Common Stock publicly traded?
Yes, Ocugen, Inc. - Common Stock is publicly traded.
What exchange does Ocugen, Inc. - Common Stock trade on?
Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocugen, Inc. - Common Stock?
The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
What is the current price of Ocugen, Inc. - Common Stock?
The current price of Ocugen, Inc. - Common Stock is 0.7679
When was Ocugen, Inc. - Common Stock last traded?
The last trade of Ocugen, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Ocugen, Inc. - Common Stock?
The market capitalization of Ocugen, Inc. - Common Stock is 197.60M
How many shares of Ocugen, Inc. - Common Stock are outstanding?
Ocugen, Inc. - Common Stock has 198M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap